Physician profile
Thomas E Griffin
NPI 1023038031
$398.20
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2021: $15.01 · 2022: $15.71.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $106.55 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $46.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $40.67 | 2019 | |
| Amgen INC. | $35.77 | 2019 | |
| Novo Nordisk INC | $32.03 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.72 | 2019 | |
| Pfizer INC. | $28.76 | 2019-2021 | |
| Abbvie INC. | $16.95 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.83 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.71 | 2022 | |
| Glaxosmithkline, LLC. | $15.43 | 2019 | |
| Lilly USA, LLC | $12.06 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.